

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 July 2024 (11.07.2024)



(10) International Publication Number
WO 2024/146930 A1

(51) International Patent Classification:
C12N 15/115 (2010.01) A61P 9/10 (2006.01)
A61P 21/00 (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/EP2024/050174

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(22) International Filing Date:
04 January 2024 (04.01.2024)

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
23382006.7 05 January 2023 (05.01.2023) EP

(71) Applicant: **APTATARGETS, S.L.** [ES/ES]; Avda Car-
denal Herrera Oria, Num. 298 Planta 1, Puerta 4, 28035
MADRID (ES).

(72) Inventors: **HERNÁNDEZ JIMÉNEZ, Macarena**; Avda
Cardenal Herrera Oria, Num. 298, Planta 1, Puerta 4, 28035
MADRID (ES). **SEGARRA DE LA PEÑA, David**; Av-
da Cardenal Herrera Oria, Num. 298, Planta 1, Puerta 4,
28035 MADRID (ES). **ZARABOZO LEAL, María Euge-
nia**; Avda Cardenal Herrera Oria, Num. 298, Planta 1, Puer-
ta 4, 28035 MADRID (ES).

(74) Agent: **ZBM PATENTS - ZEA, BARLOCCI & MARK-
VARDESEN**; Rambla de Catalunya, 123, 08008 Barcelona
(ES).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: APTOLL MOLECULES FOR THE TREATMENT OF ISCHEMIC STROKE AND INTRACRANIAL HEMORRHAGES

(57) Abstract: The APRIL study showed that the infusion of ApTOLL 0.2 mg/kg (SEQ ID NO: 1) in combination with endovascular treatment in selected stroke patients is safe and reduces the mortality at 90 days. ApTOLL has demonstrated that limit the phenomena of intracranial hemorrhages and reperfusion damage that may occur after recanalization, and also improves early neurological impairment and long term disability. ApTOLL molecules are provided for use in reducing the risk of intracranial or secondary hemorrhages, in reducing the neurological damage and in improving the neurological recovery after an acute ischemic stroke in a subject.

WO 2024/146930 A1